Effects Of Empagliflozin On Uric Acid Levels And Gout: Observations From The Empa-Reg Outcome Trial

Background Higher serum uric acid (UA) levels are associated with gout and other adverse outcomes in patients with type 2 diabetes (T2D). Sodium glucose co-transporter 2 inhibitors lower UA and may reduce gout flares. We studied on-treatment effects of empagliflozin on serum UA levels, prescription of anti-gout/UA-lowering medication, and gout flares in 7020 patients (pooled empagliflozin n=4687; placebo n=2333) with T2D and high CV risk treated in EMPA-REG OUTCOME.